Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Lipids as Anchors

Lipids as Anchors

In the plasma membrane, the lipids forming the bilayer can also act as an anchor to tether proteins to the membrane. The three main types of lipid anchors found in eukaryotes are – prenyl groups, fatty acyl groups, and glycosylphosphatidylinositol or GPI groups. Prenyl and fatty acyl groups act as anchors on the cytosolic surface of the membrane, whereas GPI anchors proteins on the extracellular side.
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Polygenic risk score analysis of noise-induced hearing loss: An integrated cross-sectional and longitudinal study.

Hearing research·2026

Same author

Advances and Prospects of ZIF-Based Nanoplatforms for Therapeutic and Diagnosis Strategies in Endocrine Diseases.

ACS applied bio materials·2026

Same author

Sympathetic immunomodulation suppresses liver metastasis by maintaining the balance between norepinephrine concentration and the α2a/β2-AR ratio.

Cellular & molecular immunology·2026

Same author

AS1411 aptamer-functionalized, cell membrane-camouflaged nanoparticles for targeted tumor cells imaging in the Raman silent region.

Analytical and bioanalytical chemistry·2026

Same author

NRAC: an emerging nutrient-responsive regulator of tissue-specific fatty acid metabolism.

Biochemical and biophysical research communications·2026

Same author

Correction: An EGFRvIII targeted dual-modal gold nanoprobe for imaging-guided brain tumor surgery.

Nanoscale·2026

Same journal

Precision gene editing: From proof-of-concept to curative therapies.

Trends in molecular medicine·2026

Same journal

Targeting ferroptosis halts graft deterioration in transplantation.

Trends in molecular medicine·2026

Same journal

Amyotrophic lateral sclerosis: A rare but aggressive adult-onset disease.

Trends in molecular medicine·2026

Same journal

Urticaria: A debilitating disorder with emerging therapies.

Trends in molecular medicine·2026

Same journal

Gene therapy for aging and longevity.

Trends in molecular medicine·2026

Same journal

The emerging role of PPARs in primary biliary cholangitis.

Trends in molecular medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 12, 2026

Click-Chemistry Based Fluorometric Assay for Apolipoprotein N-acyltransferase from Enzyme Characterization to High-Throughput Screening

Click-Chemistry Based Fluorometric Assay for Apolipoprotein N-acyltransferase from Enzyme Characterization to High-Throughput Screening

Published on: May 13, 2020

ANGPTL3/8: one target, multiple lipid disorders.

¹Center for Molecular Medicine and Genetics, Wayne State University Medical School, Detroit, MI 48202, USA.

Trends in Molecular Medicine

|October 30, 2025

Summary

This summary is machine-generated.

Selective blockade of the angiopoietin-like protein (ANGPTL)3/8 complex effectively lowers triglycerides and raises HDL-cholesterol. This approach shows promise as a precision therapy for various dyslipidemias.

Keywords:

ANGPTL3 ANGPTL8 APOA5 CREBH triglyceride

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Related Experiment Videos

Last Updated: Jan 12, 2026

Click-Chemistry Based Fluorometric Assay for Apolipoprotein N-acyltransferase from Enzyme Characterization to High-Throughput Screening

Click-Chemistry Based Fluorometric Assay for Apolipoprotein N-acyltransferase from Enzyme Characterization to High-Throughput Screening

Published on: May 13, 2020

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Area of Science:

Biochemistry and Molecular Biology
Cardiovascular Medicine
Metabolic Disorders

Background:

The angiopoietin-like protein (ANGPTL)3/8 complex is a key regulator of triglyceride metabolism.
Dyslipidemia, characterized by abnormal lipid levels, is a major risk factor for cardiovascular disease.
Current therapies have limitations in addressing complex lipid disturbances.

Purpose of the Study:

To evaluate the therapeutic potential of selectively blocking the ANGPTL3/8 complex.
To investigate the impact of ANGPTL3/8 antagonism on triglyceride and HDL-cholesterol levels.
To explore ANGPTL3/8 antagonism as a precision medicine approach for dyslipidemias.

Main Methods:

Inhibition of the ANGPTL3/8 complex.
Assessment of lipid partitioning.
Analysis of clinical and genetic data related to dyslipidemia.

Main Results:

Selective blockade of ANGPTL3/8 complex leads to reduced triglyceride levels.
HDL-cholesterol levels are increased following ANGPTL3/8 blockade.
Evidence supports ANGPTL3/8 antagonism for conditions like mixed dyslipidemia and monogenic hypertriglyceridemia.

Conclusions:

ANGPTL3/8 antagonism represents a promising therapeutic strategy for dyslipidemia.
This approach offers a precision therapy by correcting fundamental lipid partitioning disturbances.
Further research supports its application in genetic and acquired dyslipidemias.